Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities in Animal Health

 Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities in Animal Health

Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities in Animal Health

Shots:

  • Boehringer Ingelheim has acquired Global Stem cell Technology (GST) focusing to strengthen its portfolio capabilities to accelerate innovation and growth
  • The acquisition follows two years of partnership b/w the companies that brought the first-ever registered stem cell-based veterinary medicine (Arti-Cell Forte) in the EU
  • The acquisition of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals. Arti-Cell Forte is testimony to the innovation strength that lies within both companies

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: GST

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post